phase II trial carboplatin vinblastin treatment advanc squamou cell carcinoma esophagu cisplatin-contain regimen activ treatment esophag cancer respons rate advanc diseas carboplatin toxic cisplatin singl agent sever respons esophag tumor role carboplatin esophag cancer author chemotherapy-na patient advanc squamou cell carcinoma esophagu carboplatin vinblastin carboplatin IV day week vinblastin IV day week major respons signific renal toxic mild gastrointestin toxic emesi diarrhea hematolog toxic sever patient prior radiat therapi RT patient prior RT grade hematolog toxic toxic cisplatin-contain regimen carboplatin vinblastin activ treatment squamou cell carcinoma esophagu hematolog toxic regimen sever patient RT 